Factors impacting compliance with palmzumab prophylaxis [4]

Pediatric Infectious Disease Journal

Volumn 23, Issue 2 SUPPL., 2004, Pages 186-187

  Pignotti, Maria Serenella ^a   Indolfi, Giuseppe ^a   Donzelli, Gianpaolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Compliance; Newborn; Palivizumab; Respiratory syncytial virus

Indexed keywords

ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; PALIVIZUMAB;

CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC APPROACH ROUTE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; INFANT; INFECTION PREVENTION; ITALY; LANGUAGE; LETTER; MALE; METHODOLOGY; NEWBORN; PATIENT COMPLIANCE; PREMATURITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; ITALY; MALE; PATIENT COMPLIANCE; PRIMARY PREVENTION; PROGNOSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 1242291803     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000110271.48794.a7     Document Type: Letter

References (7)

1. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
2. Groothuis JR for the Northern Hemisphere Expanded Access Study Group Safety and tolerance of administration in a large northern hemisphere trial. Pediatr Infect Dis J 2001;20:628-30.
3. Sorrentino M, Powers T, and the Outcomes Study Group. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J 2000;19:1068-71.
4. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: Indications for the use of and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-16.
5. Società Italiana di Pediatria, Raccomandazioni per la prevenzione della malattia da virus respiratorio sinciziale (RSV). Ital J of Pediatrics 2000;26:379-81.
6. Langkamp DL, Hlavin SM. Factors predicting compliance with palivizumab in high-risk infants. Am J Perinatol 2001; 18:345-52.
7. Caritas Diocesana Roma. I nuovi numeri dell'immigrazione. Available at: http://www.caritasroma.it/settori/comunicazi-one/Comunicati/2003-05-13.pdf. July 7, 2003.